secwatch.observer — SEC 8-K summary
======================================

Issuer:     GALECTIN THERAPEUTICS INC (GALT)
CIK:        0001133416
Form:       8-K
Filed at:   2024-03-29T23:59:59+00:00
Accession:  0001140361-24-016454
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galectin Therapeutics reports FY2023 net loss of $44.8M; cash runway through March 2025
--------------------------------------------------------------------------------

- Net loss applicable to common stockholders of $44.8M ($0.74/share) vs $38.9M ($0.65/share) in FY2022.
- Cash and equivalents $25.7M at Dec 31; plus $20M available credit line and new $10M facility from chairman.
- NAVIGATE Phase 2b/3 trial for belapectin in MASH cirrhosis fully enrolled (357 patients); interim analysis readout expected Q4 2024.
- Appointed Benjamin S. Carson, Sr., M.D. to Board of Directors.
- Fourth DSMB meeting authorized continuation of NAVIGATE trial without modifications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133416/000114036124016454/0001140361-24-016454-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133416/000114036124016454/ef20025022_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-016454

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer